Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Successfully Enrolls Targeted Number of Patients in Phase 3 Study of Prolastin®-C for Emphysema Due to Alpha-1-Antitrypsin Deficiency Grifols, a global leader in plasma-derived medicines, has achieved its enrollment goal of 339 patients for the SPARTA clinical trial. This groundbreaking study aims to assess the effectiveness and safety of two different weekly doses of Grifols' Prolastin®..